We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Global COVID-19 Test Kits Market to Surpass USD 13 Billion by 2026

By LabMedica International staff writers
Posted on 23 Sep 2020
Print article
Illustration
Illustration
The global COVID-19 test kits market with a current market value of USD 15.4 billion in 2020 is expected to record revenue of more than USD 13 billion by 2026, driven primarily by the high efficiency and accuracy of RT-PCR based COVID-19 detection kits for the detection of the SARS-CoV-2 virus.

Given the ongoing COVID-19 pandemic, the demand for COVID-19 test kits is anticipated to surge in the near future. The number of COVID-19 cases is increasing rapidly across the globe. The resumption of industrial and economic activities in high burden countries is expected to drive a further increase in the number of COVID-19 cases. These are the latest findings of Global Market Insights, Inc. (Selbyville, DE, USA), a global market research and consulting service provider.

On the basis of product, the immunoassay cassettes or test strips segment held a share of over 29% in the global COVID-19 test kits market in 2020 due to the surging demand for immunoassay-based COVID-19 detection kits, as these tests have less manufacturing costs and are easy to perform. Immunoassays can detect past infections by examining the immune response of the patient during as well as after the COVID-19 infection. On the basis of specimen type, the nasal swab segment accounted for revenue of more than USD 1.8 billion in 2020, owing to the wide availability and easy operation of nasal swab specimens.

Based on end-use, the hospitals segment dominated the global COVID-19 test kits market in 2020 with a share of around 46% Hospitals provide convenient access to quality care, manage healthcare spending and improve recovery. Competition among hospitals is continuously rising for providing better quality services at low prices.

Geographically, the COVID-19 test kits market in Asia Pacific will record a growth of -2.2% until 2026, driven by favorable government initiatives for the early treatment and diagnosis of COVID-19 in highly affected countries such as China, India as well as others. The presence of market players in Asia Pacific who are developing novel products will also boost the growth of the COVID-19 test kits market in the region.

Related Links:
Global Market Insights, Inc.

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.